Global Anti-nuclear Antibody (ANA) Testing Market -  Forecast To 2027

Anti-nuclear Antibody (ANA) Testing Market information, by type (immunofluorescence, enzymelinked, immunosorbent assay (ELISA) and others), by application (Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Polymyositis, Scleroderma, Sjögren's syndrome, and others), by End User (Hospitals and clinics, research laboratories, and others) - Forecast to 2027

ID: MRFR/LS/2319-HCR | February 2023 | Region: Global | 72 Pages         

Anti-nuclear Antibody (ANA) Testing Market

The Anti-nuclear Antibody (ANA) testing market will acquire a CAGR of 9.6 % and a value of US$ 1300.6 million from 2020 to 2027.

By Type immunofluorescence enzymelinked immunosorbent assay
By Application Rheumatoid arthritis Systemic lupus erythematosus (SLE) Polymyositis Scleroderma Sjögren's syndrome and others
By End User Hospitals and clinics research laboratories and others
Key Players
Companies Profiled   Abcam plc. (US)    Alere (US)    Antibodies Inc.(US)    Bio-Rad Laboratories    Erba Diagnostics (US)    Indur Services    MBL INTERNATIONAL (US)    Merck KGaA (Germany)    Trinity Biotech (Republic of Ireland)
Market Driving Forces   Increasing technological advancements    adoption of new techniques and increasing prevalence of various autoimmune diseases
Request a Free Sample

Antinuclear Antibody (ANA) Testing Market Overview

The Anti-nuclear Antibody (ANA) testing market will acquire a CAGR of 9.6 % and a value of US$ 1300.6 million from 2020 to 2027.

Antinuclear Antibody (ANA) Test detects antinuclear antibodies in the blood. The immune system makes antibodies to fight infections. Antinuclear antibodies attack on own tissues. It helps to recognize autoimmune diseases such as rheumatoid arthritis and lupus. The rise in technological advancements, higher adoption rate of new techniques, and growing concern of autoimmune diseases are driving the antinuclear antibody (ANA) testing market growth. Major industrial players are investing in research and development for the development of advanced products, which is another key growth factor for the market.

North America holds the prime position in Anti-nuclear Antibody (ANA) Testing market. U.S. hold the largest share and the European region is the second-largest and due to the higher growth rate in west European countries. The Asia-Pacific (APAC) is rapidly growing and significantly maintains a significant growth rate in the forecast period. The Middle East and Africa (ME&A) will show limited growth due to less awareness of devices and treatment. This regional development will boost the global growth rate of the market.

Key Players for Anti-nuclear Antibody (ANA) Testing Market:  

Some of the key players in this market are: Abcam plc. (US), Alere (US), Antibodies Inc.(US), Bio-Rad Laboratories, Inc. (US), Erba Diagnostics (US), Indur Services, Inc. (US), MBL INTERNATIONAL (US), Merck KGaA (Germany), Trinity Biotech (Republic of Ireland)

Intended Audience

  • Anti-nuclear Antibody (ANA) Test products manufacturers

  • Anti-nuclear Antibody (ANA) Test products and services providers

  • Medical Research laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors

Market Segments:  

Anti-nuclear Antibody (ANA) Testing Market has been segmented on the basis of type which comprise immunofluorescence (Primary or direct and Secondary or indirect), enzymelinked, immunosorbent assay (ELISA) (Direct ELISA, Indirect ELISA, Sandwich ELISA, Competition/Inhibition ELISA), and others. On the basis of application, it segmented into Rheumatoid arthritis (Seropositive, Seronegative), Systemic lupus erythematosus (SLE) (Discoid lupus erythematosus, Subacute cutaneous lupus erythematosus, Neonatal lupus), Polymyositis, Scleroderma (localized scleroderma, systemic scleroderma), Sjögren's syndrome (Primary, secondary) , and others. On the basis of end user, it segmented into Hospitals and clinics, research laboratories, and others.



Study objectives of Anti-nuclear Antibody (ANA) Testing Market:

  • To provide detailed analysis of the Anti-nuclear Antibody (ANA) Testing market structure with historical and forecast revenue for the next 7 years of the various segments and sub-segments of the Anti-nuclear Antibody (ANA) Testing Market

  • To provide insights about the key drivers, restraints, opportunities and challenges that affecting the growth of the Anti-nuclear Antibody (ANA) Testing market

  • To provide analysis of the market with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide detail analysis of the market that segmented on the basis of type, by application, by end user, and its sub-segments.

  • To provide detail analysis of Anti-nuclear Antibody (ANA) testing market mainly based on value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.

  • To provide detail country level analysis of the market with respect to the current market size and future prospective

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Anti-nuclear Antibody (ANA) Testing Market

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Anti-nuclear Antibody (ANA) Testing market

Regional Analysis of Anti-nuclear Antibody (ANA) Testing Market:       

Considering the global scenario of the market, North America is largest market for Anti-nuclear Antibody (ANA) Testing, in North America region US hold largest market share while European market is second largest, and especially the growth rate is higher in west European countries. On the other hand, Asia-Pacific (APAC) is fastest growing market and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of devices and treatment.Recent Development

In May 2022

The U.S. Food and Drug Administration (FDA) has cleared ZEUS Scientific's dIFine® digital immunofluorescence system* for use with ZEUS' ANA HEp-2 indirect fluorescent antibody (IFA) assay.

The FDA-cleared ZEUS dIFine® digital immunofluorescence system is the next generation in IFA imaging and pattern recognition designed to acquire, analyze, display and store digital images of ZEUS IFA HEp-2 cells. An automated digital scanner with intelligent software, ZEUS dIFine quickly delivers positive/negative results and has been programmed to suggest eight common ANA HEp-2 patterns (homogenous, speckled, centromere, nucleolar, nuclear dots, nuclear membrane, cytoplasmic (ribosomal and mitochondrial)). dIFine also instantly locates and identifies mitotic cells to assist in pattern identification. Quickly viewing and validating all negative samples with a single mouse click saves the user valuable time.

Anti-nuclear Antibody (ANA) Testing Market, by Region

  • Americas

    • North America

      • US

      • Canada

    • Latin America

  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Middle East

    • Africa

Research Methodology: Research Methodology Anti-nuclear Antibody (ANA) Testing Market

 Sources: Directorate of Industries, Annual report, White paper, Company Presentation

The report for Anti-nuclear Antibody (ANA) Testing Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Anti-Nuclear Antibody Testing Market is projected to grow at a 9.6% CAGR between 2017-2023.

Anti-Nuclear Antibody Testing Market predicted to touch USD 1300.6 million by 2023.

North America is expected to dominate the Anti-Nuclear Antibody Testing Market.

Different end user industries of Anti-Nuclear Antibody Testing Market include research laboratories, hospital and clinics, and others.

Different strategies used by market players to create a dominance in the Anti-Nuclear Antibody Testing Market include mergers, acquisitions, collaborations, and product launches.